TELCON RF PHARMACEUTICAL. Inc.

As of June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. carries a market capitalization of 17.34B, placing it among publicly traded companies globally. Its enterprise value stands at 70.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. has 7.15M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.22, and the price-to-book ratio stands at 0.24.

As of June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. trades at an EV/EBITDA multiple of 11.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 181.55 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 70.05B versus a market cap of 17.34B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. maintains a current ratio of 0.90, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.47, indicating elevated leverage, while an interest coverage ratio of 1.59 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. posted a negative return on equity (ROE) of -25.21, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.90, reflecting losses generated across the asset base. The company generates approximately 464.54M in revenue per employee across its workforce of 133.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.87 indicates how many times TELCON RF PHARMACEUTICAL. Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. recorded an income tax benefit of -52.41M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -27.04B and -17.48B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, TELCON RF PHARMACEUTICAL. Inc.'s stock has declined approximately 79.70% over the past 52 weeks. The 50-day moving average sits at 2,223.60, while the 200-day moving average is 6,085.97.

Over the twelve months ended June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. generated 61.78B in revenue and converted that into -17.48B in net income, yielding earnings per share of -4,720.84. EBITDA reached 6.29B, while operating income came in at 386.01M.

As of June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. holds 36.58B in cash and equivalents against 63.15B in total debt, resulting in a net debt position of 40.77B. Total book value stands at 73.34B, with working capital of -8.34B providing operational flexibility.

TELCON RF PHARMACEUTICAL. Inc. produced 1.87B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.83B in capital expenditures, free cash flow totaled 47.07M - equivalent to 8.23 per share.

Over the twelve months ended June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. posted a gross margin of 34.98, reflecting its pricing power and cost economics. The operating margin of 0.62 and net profit margin of -28.29 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.34, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -79.04, meaning TELCON RF PHARMACEUTICAL. Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

TELCON RF PHARMACEUTICAL. Inc.'s most recent stock split took place on June 30, 2026 with a 10:1 split ratio.

As of June 30, 2026, TELCON RF PHARMACEUTICAL. Inc. has an Altman Z-Score of -0.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.